CEO & founder

Dr Kate Cameron performs pioneering work within liver cell physiology and differentiation of drug-inducible hepatocytes from human ES and iPS cells. She has over 10 years in stem cell experience and 5 in hepatocyte differentiation. She has pushed the front line forward by making cGMP translatable hepatocytes in a defined system, this has been published and patented.  She has led the way in optimising hepatocyte differentiation in automated systems and developing Cytochroma as a business.
She has recently begun the prestegious Royal society of Edinburgh Enterprise Fellowship programme, funded by the BBSRC.